Navigation Links
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Date:3/18/2009

PRINCETON, N.J., March 18 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced that it completed enrollment in its pivotal Phase III study of nonpegylated liposomal doxorubicin (Myocet(TM)) in metastatic HER-2-overexpressing breast cancer. This is a pivotal Phase III trial of Sopherion's lead product in combination with the current standard of care, paclitaxel (Taxol) and trastuzumab (Herceptin(R)), vs. paclitaxel and trastuzumab alone. Progression-free survival (PFS) is the primary efficacy endpoint, with careful monitoring for cardiac safety.

Dr. Jose Baselga, Chairman & Professor of Medicine, Vall d'Hebron Institute of Oncology (V.H.I.O.), Vall d'Hebron University Hospital in Barcelona, Spain, and principal investigator for the trial, said, "I am pleased to see that the recruitment phase of the Phase III trial has now been completed. This registration trial is based on our recently published, Roche-supported study conducted by the Spanish Breast Cancer Cooperative Group (SOLTI). Results showed that Myocet, in combination with trastuzumab and paclitaxel treatment, yielded an unusually high clinical response rate and time to progression in patients with HER-2 overexpressing breast cancer; the 3 drug combination was well tolerated with no cases of treatment-related symptomatic congestive heart failure. "

Phase III Study Design

The study is a global, randomized, multicenter pivotal Phase III study in 363 patients who have metastatic HER-2-overexpressing breast cancer. Eligibility criteria included no prior chemotherapy for metastatic disease, nor any trastuzumab, anthracyclines or taxanes within the previous 12 months. Eligible patients were randomized to receive either Myocet, paclitaxel and trastuzumab, or paclitaxel and trastuzumab alone in a 1:1 randomiza
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Whitehouse Laboratories is pleased to ... County (New Jersey) Chamber of Commerce as a ... organization in the North Jersey area, offers Whitehouse ... key clients in the pharmaceutical and biotechnology areas ... Membership enables Whitehouse Laboratories a higher level of ...
(Date:11/26/2014)... Charlotte, NC (PRWEB) November 25, 2014 ... High Intensity Focused Ultrasound (HIFU) devices, recently participated ... “ Small Renal Mass 360° .” Key opinion ... and therapeutic advances related to small renal masses ... learn about different ablative technologies in hands-on labs. ...
(Date:11/26/2014)... Silicon Valley Electronic Data Capture (EDC) provider ... provider of clinical research and data management services to ... its CRO Partnership Program, Clinovo expands ClinCapture , ... , “We have found Clinovo’s ClinCapture to exceed our ... is both user friendly and easy to deploy. The ...
(Date:11/26/2014)... Continuing its award-winning streak, Nerium International, the leader ... for outstanding creative achievement by its marketing and communication ... organization’s top honor, in the Branding category for its ... of this year. The event showcased top speakers and ... awarded a Gold MarCom Award in the Special Events ...
Breaking Biology Technology:Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 3SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2
... Additional "FOR" Votes Required for Integra Merger, IRVINE, ... ("IsoTis"), an orthobiologics company, today reported that,less than 100,000 ... by Integra LifeSciences Holdings Corporation (NASDAQ: IART ),("Integra") ... as of August,6, 2007. Today,s special meeting of ...
... 26 PURE Bioscience (OTC,Bulletin Board: PURE), creators ... in a revolutionary new hard surface,disinfectant which kills ... the Company will present at the Biocom Investor ... Diego Marriott Del Mar. Michael L.,Krall, CEO, will ...
... Oct. 26 Pharmasset, Inc.,(Nasdaq: VRUS ) management will be ... Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference being ... York Palace Hotel in New York City. ... Officer, will provide an overview of the company on Tuesday, ...
Cached Biology Technology:IsoTis Reports Status of Merger Vote 2IsoTis Reports Status of Merger Vote 3IsoTis Reports Status of Merger Vote 4PURE Bioscience to Present at Biocom Investors Conference 2PURE Bioscience to Present at Biocom Investors Conference 3PURE Bioscience to Present at Biocom Investors Conference 4Pharmasset to Present at Three Investor Conferences in November 2007 2
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
(Date:11/21/2014)... 19, 2014  Earlier this year Donald Spector ... and one of the most prolific inventors in the ... transmitted from Smartphones to third party agencies. Spector envisioned ... one of the earliest known patents in this area. ... the military, child care, elder care and hospital applications. ...
(Date:11/21/2014)... 20, 2014 Strict laws against distracted driving ... the North American and European automotive sector towards gesture ... recognition systems that are intuitive and able to retrieve ... industry. New analysis from Frost & ... in Europe and ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... 2009) Based on a striking similarity between heart ... Medical Center have discovered that a new class of ... the fatal muscular disorder. At first glance, heart ... dissimilar. Duchenne affects boys usually before the age of ...
... Georgia Facility to Recycle Wood Waste and Generate ... Energy Systems, a subsidiary of the diversified renewable ... Alternext US: GNH), announced the execution of a ... wood fuel and landscape materials processor, WoodTech, LLC, ...
... polls, new legal challenges, ,intelligent design in the courts, ... Scopes was finally vindicated, ,creationism was booted out of ... speech issued a clarion call to "restore science to ... battered every day in school ,districts across the U.S. ...
Cached Biology News:While focusing on heart disease, researchers discover new tactic against fatal muscular dystrophy 2Global Energy Systems to Acquire WoodTech, LLC, and Affiliated Entities 2Global Energy Systems to Acquire WoodTech, LLC, and Affiliated Entities 3US science education organization updates analysis 2
... RNase Inhibitor (patent pending) is a protein ... binds and inhibits the most common and ... 1 and T1. SUPERaseIn can be used ... be problematic. It is ideal for in ...
... recombinant protein that has been shown to help ... of cDNA by reverse transcription, in vitro RNA ... Safe Inhibitor tightly binds RNases in a 1:1 ... RNases such as RNase A, RNase B, RNase ...
... RNase Inhibitor (Ribonuclease inhibitor) ... enzyme used to inhibit RNase ... DNase or endonuclease activity. , ... degradation of RNA template ...
... GC-rich nucleic acids ,The GC-RICH PCR ... and a proofreading polymerase, powers through templates ... with other polymerases and other blends of ... and the unique GC-RICH Resolution Solution combine ...
Biology Products: